title: Clinical outcome in children with chronic recurrent multifocal osteomyelitis.
abstract: OBJECTIVE
  To determine the clinical outcome of children with chronic recurrent multifocal osteomyelitis (CRMO).
  
  
  METHODS
  We retrospectively reviewed clinical, biological and radiological data of children with CRMO at five French paediatric centres. Outcome data were obtained through review of hospital charts and questionnaires sent to all patients to assess disease activity and educational and vocational achievement.
  
  
  RESULTS
  Forty patients were assessed (34 females and 6 males) with a median age at diagnosis of 11.5 yrs (range 2-17). Median number of initial bony lesions was 2 at onset, and 3.5 over disease course. Median time since diagnosis was 3.5 yrs (range 0.5-15) and median duration of active disease 2.7 yrs (range 0.5-13.5). Nine (22.5%) patients had psychological or physical sequelae. Twenty-nine children (72.5%) responded to the questionnaire. Twenty-six had no physical disability as judged by the HAQ 0-1, two had moderate disability (HAQ: 1-2) and one had severe disability (HAQ: 2-3). Seventeen patients (58.6%) had active disease at follow-up (after 6 months to 15 yrs since diagnosis) and continued to have pain (median value of visual analogue scale: 10/100). CRMO had interfered with patient's education in two cases.
  
  
  CONCLUSIONS
  Clinical outcome of children with CRMO is generally good, but a sizeable proportion of patients have active disease at follow-up, and a minority of patients can have a severe and prolonged disease course despite intensive treatments. Further studies are required to determine predictive factors for severe disease.
authors.affiliation: Service de Pédiatrie Générale, Centre hospitalier d'Avignon, 305, rue Raoul Follereau, 84902 Avignon cedex 9, France. chacatalano@yahoo.fr
authors.forename: C
authors.initials: C
authors.lastname: Catalano-Pons
authors.forename: A
authors.initials: A
authors.lastname: Comte
authors.forename: J
authors.initials: J
authors.lastname: Wipff
authors.forename: P
authors.initials: P
authors.lastname: Quartier
authors.forename: A
authors.initials: A
authors.lastname: Faye
authors.forename: D
authors.initials: D
authors.lastname: Gendrel
authors.forename: A
authors.initials: A
authors.lastname: Duquesne
authors.forename: R
authors.initials: R
authors.lastname: Cimaz
authors.forename: C
authors.initials: C
authors.lastname: Job-Deslandre
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010019:Osteomyelitis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal